(Q35056070)

6 August 2017

1 reference

title

Sjogren's syndrome: evolving therapies (English)

1 reference

6 August 2017

Robert I Fox

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

247-254

1 reference

Current issues in Sjögren's syndrome.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Sjögren's syndrome: current therapies remain inadequate for a common disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Self-perceived oral health status, psychological well-being, and life satisfaction in an older adult population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

The relationship between dental status and health-related quality of life in upper aerodigestive tract cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

A comparison of the validity of generic- and disease-specific measures in the assessment of oral health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Assessing change in quality of life using the Oral Health Impact Profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Use of orally administered anhydrous crystalline maltose for relief of dry mouth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Fluoride and urea chewing gums in an intra-oral experimental caries model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Anethole dithiolethione regulates oxidant-induced tyrosine kinase activation in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Anethole dithiolethione: biochemical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

The impact of gene therapy on dentistry: a revisiting after six years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Update in Sjögren syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Gas-permeable scleral contact lens therapy in ocular surface disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Primary Sjögren's syndrome with central nervous system disease mimicking multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Primary Sjögren's syndrome manifested as multiple sclerosis and cutaneous erythematous lesions: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

The relationship between infliximab treatment and lymphoma in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Experiences with leflunomide in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.247

RETRACTED: Infliximab in patients with primary Sjögren's syndrome: a pilot study

21 January 2018

0 references

Identifiers

DOI

10.1517/13543784.12.2.247

1 reference

6 August 2017

1 reference